INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.

INSILICO (03696) announced that it has reached an agreement with Eli Lilly and Company for authorization and drug development cooperation. Both parties will utilize INSILICO's AI pharmaceutical capabilities to accelerate the discovery and development of new therapies in multiple treatment areas. Under the agreement, Eli Lilly will receive a global exclusive license to develop, manufacture, and commercialize a new oral therapy targeting specific indications, currently in the preclinical development stage, with the potential to become best-in-class. In addition, leveraging INSILICO's advanced Pharma.AI platform capabilities and Eli Lilly's expertise in research and disease areas, INSILICO and Eli Lilly will also collaborate on multiple research and development projects focused on Eli Lilly's selected targets. According to the terms of the agreement, INSILICO will be eligible to receive an initial payment of $115 million, with further payments upon reaching development, regulatory, and commercialization milestones, bringing the total deal value to a maximum of approximately $2.75 billion; in addition, INSILICO will also receive tiered royalties based on future sales.